is currently in its Phase 2 clinical trial of Pitolisant, studying the safety and impact of an investigational medicine for excessive daytime sleepiness, cognition, and behavioral function in people with PWS. This week, they added an 11th location to their list of trial sites around the U.S. The trial site will be located at CTI Clinical Trial and Consulting Services, Inc.
in Cincinnati, OH and will be led by Dr. James Maynard, who is board certified in both neurology and sleep medicine.
Participation in the trial lasts approximately four months. During that time, there are five planned visits.